US 11,859,168 B2
Electroporation, developmentally-activated cells, pluripotent-like cells, cell reprogramming and regenerative medicine
Christopher B. Reid, Los Angeles, CA (US); Melissa Braga, Monterey Park, CA (US); Lilian N. Santamaria, Los Angeles, CA (US); Ashley N. Wickrema, Los Angeles, CA (US); Marinne D. Wickrema, Los Angeles, CA (US); Anthony Hao Dinh, Garden Grove, CA (US); Yaman Eksioglu, Atlanta, GA (US); and Mat Hoang Ho, Birmingham, AL (US)
Assigned to Christopher B. Reid, Los Angeles, CA (US)
Filed by Christopher B. Reid, Los Angeles, CA (US)
Filed on Sep. 24, 2019, as Appl. No. 16/579,889.
Application 16/579,889 is a continuation in part of application No. 16/171,420, filed on Oct. 26, 2018, abandoned.
Application 16/171,420 is a continuation in part of application No. 14/764,195, granted, now 10,138,451, issued on Nov. 27, 2018, previously published as PCT/US2014/013473, filed on Jan. 29, 2014.
Application 16/171,420 is a continuation in part of application No. 16/579,889.
Application 16/579,889 is a continuation in part of application No. 12/601,819, abandoned, previously published as PCT/US2008/065007, filed on May 28, 2008.
Claims priority of provisional application 61/849,589, filed on Jan. 30, 2013.
Claims priority of provisional application 61/064,761, filed on Mar. 25, 2008.
Claims priority of provisional application 60/933,670, filed on Jun. 8, 2007.
Claims priority of provisional application 60/933,133, filed on Jun. 5, 2007.
Claims priority of provisional application 60/932,020, filed on May 29, 2007.
Prior Publication US 2020/0048600 A1, Feb. 13, 2020
Prior Publication US 2023/0340397 A9, Oct. 26, 2023
Int. Cl. C12M 1/00 (2006.01); C12M 1/42 (2006.01); C12N 15/11 (2006.01); C12M 3/00 (2006.01); C12N 15/10 (2006.01); A61K 48/00 (2006.01); C12Q 1/6811 (2018.01)
CPC C12M 43/00 (2013.01) [A61K 48/0058 (2013.01); C12M 21/00 (2013.01); C12M 23/42 (2013.01); C12M 35/02 (2013.01); C12N 15/102 (2013.01); C12N 15/1024 (2013.01); C12N 15/1031 (2013.01); C12N 15/111 (2013.01); A61K 48/0066 (2013.01); A61K 48/0091 (2013.01); C12N 2310/141 (2013.01); C12Q 1/6811 (2013.01)] 26 Claims
 
1. A method of cellular reprogramming for the interconversion of a differentiated or somatic cell of a first cell phenotype to at least one desired second, multipotent, pluripotent, self-renewing or differentiating phenotype, the method comprising:
transfecting a nucleated cell, wherein one or more transfection step is performed in vitro or in vivo, and wherein said nucleated cell is transfected with: a) a nucleic acid, b) a vector, c) a vector comprising synthetic oligonucleotides, d) a vector for gene therapy, e) a virus, f) a polypeptide, g) a ribonucleic acid or h) a deoxyribonucleic acid encoding a polypeptide, and wherein said polypeptide is;
i. one or more first polypeptide(s) selected from PRR+ Numb, Oct3/4, Sox2, Nanog and a polypeptide with LIF activity;
ii. one or more second polypeptide(s) selected from PRR+ Numb, Oct4, Sox2, Nanog, Notch, Fgf4, Hoxb4, Lin28, Lif, Lifr, Cntf, Cardiotrophin, Osm, Osm-r, Il6, Il6r, Hyper Il6, Il-11, Gp130, Stat3, C-myc, and a polypeptide with Lif Activity;
iii. one or more third polypeptide(s) selected from a short Numb isoform, Numblike, MyoD, myogenin, Myocardin, Ifrdl, Myf 5, Myf 6, Mef2, Gata 4, Gata 5, Gata 6, Sox9, CREB-binding polypeptide, Runx2, HNF-1, HNF-3, HNF-4, HNF-6, Nurr1, REN, Neurogenin1, Neurogenin2, Neurogenin3, Mash1, Phox2a, Phox2b, dHand, Gata3, Shh, FGF8, Lmx1b, Nkx2.2, Pet1, Lbx1, Rnx, PITX2, D1x2, D1x5, Ngn2, Ptx3, Gata2, REST4, Foxa2, Sox17, HLXB9, Runx1/AML, Pdxl, OLIGI, OLIG2, NOV(CCN3), and Zfp488; and/or
iv. one or more fourth polypeptide(s) altering the amount, activity or antigenicity of a cellular protein.